Alpha Tau Stock: A Billion Dollars of Market Value, Not One Dollar of Revenue — and a 67 Percent Success Rate Measured in Three Patients

Here is a number: 67 percent. Read it again — did your brain ask "of what"? Probably not, and that is not a personal failing; it is how the percent sign works on all of us. Psychologists call it denominator neglect: a rate feels like a law of nature, a measured property of the world, and the little number underneath it — the how-many-people-was-that — quietly vanishes. Ten percent of a thousand and ten percent of ten look identical on the page and are not remotely the same knowledge. In the summer of 2026 hardly any stock rewards that reflex like Alpha Tau Medical (Nasdaq: DRTS): an Israeli company that implants tiny radioactive seeds into tumors, carries two FDA Breakthrough Device Designations, won an approval in Japan in February 2026 — and is valued by the market at roughly $1.07 billion (data as of July 16, 2026). Our Reddit hype scanner counted just 2 mentions in 24 hours (ApeWisdom, as of July 16, 2026); this is not a forum rally, it is a conviction rally. So let's make a deal: we read only what Alpha Tau itself reported to the U.S. securities regulator, the SEC — a filing is honest under penalty of law — and every time a percentage shows up, we go looking for its denominator. Our material: the annual report (20-F) for 2025, filed March 9, 2026, and the interim reports (6-K) from May 2026. One housekeeping note, because it explains the paperwork: Alpha Tau is a Foreign Private Issuer — an Israeli company listed in New York — so it files a 20-F once a year and 6-K interim reports rather than the 10-K and 10-Q you know from U.S. companies. At the end you will not get a verdict from us. You will get the denominators.

What Alpha Tau actually does — a sparkler inside the stain, not a floodlight through the wall

Alpha Tau Medical, headquartered in Jerusalem, is what the filings call a clinical-stage oncology therapeutics company — which is the industry's honest way of saying: we develop, we do not yet sell. The company was established in November 2015 and began operating in January 2016; the underlying technology was developed in 2003 at Tel Aviv University and its rights were bought from Althera Medical. Since March 8, 2022 the shares have traded on the Nasdaq, following a merger with the special purpose acquisition company Healthcare Capital Corp — a SPAC, that is, one of the blank-check vehicles of the 2021 boom. That origin matters for one reason we will come back to: it left warrants on the balance sheet.

The product is called Alpha DaRT, short for Diffusing Alpha-emitters Radiation Therapy, and the idea behind it is genuinely elegant. Conventional radiotherapy is a floodlight: the beam comes from outside and has to travel through healthy tissue to reach the tumor, which is exactly why dosing is a compromise between killing the cancer and sparing the patient. Alpha particles would be the better ammunition — they are biologically far more destructive — but they have a crippling flaw: their range is less than 100 micrometers, under a tenth of a millimeter. Point them at a tumor from outside and they never arrive. Alpha Tau's answer is to stop shooting from outside. The company builds tiny stainless steel or titanium seeds embedded with Radium-224 and injects them straight into the tumor with proprietary applicators. The radium itself stays attached to the seed, but as the annual report describes, "its daughter atoms detach, spontaneously decay and recoil in succession" — the decay products break loose and travel deeper into the tumor, emitting alpha particles as they go, until they stabilize in inert form. The seeds are placed a few millimeters apart so their fields overlap. Radium-224 has a half-life of about 3.7 days; the rest of the chain runs out in roughly 12 hours. In an everyday image: instead of shining a floodlight through the wall to burn out a stain, you place a handful of tiny sparklers directly inside the stain — each burns fiercely, none reaches further than a few millimeters, and within days they burn themselves out and go quiet. That is the whole pitch, and it is a good one.

The scale of the effort is real: as of December 31, 2025 the company had 11 clinical studies ongoing worldwide, across skin, head and neck, pancreatic and brain tumors, and it holds a marketing approval in Israel (August 2020) plus, since February 2026, one in Japan. Which brings us to the central tension of this analysis, and it runs through every chapter: the technology is real and the regulatory progress is datable — but the market is paying about $1.07 billion for evidence whose denominators are still counted in single and double digits, and for one pivotal trial that has no control group. How quickly an impressive percentage from a handful of patients can outrun what it actually proves is something we took apart in our analysis of Fractyl Health, where a celebrated number turned out to describe ten patients against eight. Here the arithmetic is, if anything, tighter.

Where the ticker comes from — and why our fundamental scanner does not know it

Honesty first: DRTS appears in none of our fundamental stock scanners. That is no verdict, it is systematics — our in-house stock scanner works through the Russell 3000 universe, meaning U.S. companies; Alpha Tau is legally an Israeli company whose ordinary shares (and separately traded warrants, DRTSW) list in New York, and so it falls through the grid. There is a second reason, and it is more interesting: several of the yardsticks our scanner lives on cannot be computed here at all. There is no price-to-sales ratio, because there are no sales. There is no price-to-earnings ratio, because there are no earnings. The Piotroski F-Score, a nine-point test of balance-sheet health, has almost nothing to count when a company has never booked revenue. The ticker landed on our desk through our Reddit hype scanner, which evaluates daily which micro and small caps are the talk of the U.S. stock forums (data basis: ApeWisdom): 2 mentions within 24 hours as of July 16, 2026 — near silence, which for a billion-dollar biotech is itself a finding. This is not a meme rally; whoever holds this stock holds it on the science. For Alpha Tau the setup means: no scanner metrics as guardrails, no fundamental grade from the database — only the original documents. All the more important to actually read them.

The numbers over the years — honestly appraised

Let's start with what is genuinely impressive, and with this company it is not the income statement — it is the regulatory ledger. August 2020: marketing approval in Israel for squamous cell carcinoma of the skin or oral cavity. June 2021: the FDA grants Alpha DaRT a Breakthrough Device Designation for patients with skin or oral SCC without a curative standard of care. October 2021: a second Breakthrough Device Designation, for recurrent glioblastoma. That program is a real distinction, not a marketing badge — it is reserved for devices addressing life-threatening conditions where, in the FDA's criteria, no approved alternatives exist or the device offers significant advantages, and it buys the developer closer contact with the agency and prioritized review. And February 2026: the first approval in a major market — Japan's Ministry of Health, Labour and Welfare granted shonin pre-market approval for unresectable locally advanced or locally recurrent head and neck cancer, on the basis of a trial completed in Japan plus data gathered elsewhere. In May 2026 came the operational milestone: the U.S. pivotal ReSTART trial completed enrollment with 88 patients, and the company had submitted the first module of its modular PMA application in January 2026. For a company of this size, that is a decade of patient, unglamorous work paying off.

Now the income statement, which is short because it starts where other companies' statements are already in their third line. There is no revenue line. Research and development, net ran to $26.4 million (2023), $27.0 million (2024) and $32.1 million (2025); general and administrative added $8.4 million in 2025, marketing $1.9 million. The total operating loss came to $35.7 million (2023), $36.0 million (2024) and $42.3 million (2025); the net loss was $29.2 million, $31.8 million and $42.6 million across those three years. As of December 31, 2025 the accumulated deficit stood at $190.1 million, and from inception through that date the company had raised $234.2 million in total — $225.3 million from issuing shares, $8.8 million from government grants. In the first quarter of 2026 the pace picked up sharply: R&D alone rose 53 percent to $11.0 million (prior-year quarter: $7.2 million), and the operating loss grew to $13.3 million from $9.3 million.

One number deserves genuine credit before we turn the page, because we went looking for the opposite and did not find it: there is no going-concern warning in these filings. Not a word about "substantial doubt" — the phrase that haunts the annual reports of so many clinical-stage companies, and that we found, for instance, in the auditor's opinion at Replimune. Alpha Tau states plainly that "its existing capital resources will be adequate to satisfy its expected liquidity requirements for the foreseeable future". As of March 31, 2026 the company held $80.2 million in cash, cash equivalents, short-term and restricted deposits (December 31, 2025: $76.9 million), against an operating cash burn of $26.7 million in 2025 (2024: $19.8 million). On the 2025 burn rate, that is roughly three years of air — though R&D spending is now rising at 53 percent year over year, and the company itself expects losses to "increase substantially". Remember the yardstick: the runway is real, but it is measured against a burn rate the company is deliberately accelerating.

What the filings say — the uncomfortable truths

Uncomfortable truth no. 1: ten years of operations, not one dollar of revenue

Alpha Tau began operating in January 2016. In the decade since, through a Nasdaq listing, two Breakthrough Device Designations and approvals in two countries, the company has never booked a single dollar of revenue. It says so itself, in the first bullet of its own risk summary:

"We have incurred significant losses since inception and have not generated any revenue to date. We expect to incur losses over the next several years and may not be able to achieve or sustain revenues or profitability in the future."

— Alpha Tau Medical Ltd., SEC annual report 20-F for 2025, Item 3.D "Risk Factors"

The same passage adds the sentence that sets the clock: the company's commercial revenues, if any, "will be derived from sales of products that we do not expect to be commercially available for many years, if at all". Read that clause twice — many years, if at all — and then set it beside a market value of roughly $1.07 billion. That is not an accusation; it is a description of what kind of asset this is. There is no business here to value in the ordinary sense: no revenue to multiply, no margin to model, no earnings to discount. What the market is pricing is a probability — the chance that a technology which works in a laboratory and in a few dozen patients will work in a regulated pivotal trial, get approved, get manufactured at scale, get reimbursed, and get prescribed. Every one of those five gates is still ahead. Remember the distinction: a company with no revenue is not cheap or expensive — it is a bet with a price tag.

Uncomfortable truth no. 2: the pivotal trial has no control group

This is the finding that matters most, and it is the one the headlines never carry. Alpha Tau's path to the U.S. market runs through ReSTART, its first and only pivotal trial, in patients with recurrent cutaneous squamous cell carcinoma. The FDA's investigational device exemption permits up to 86 patients at up to 25 U.S. sites; the first patient was treated in March 2023, and enrollment completed in May 2026 with 88 patients. The company plans to submit the data as part of a modular PMA application — the demanding approval route reserved for the highest-risk devices. Here is how the annual report describes the study's design:

"The pivotal study is a prospective, multi-center, single-arm, open label trial enrolling up to 86 patients with recurrent cutaneous squamous cell carcinoma."

— Alpha Tau Medical Ltd., SEC annual report 20-F for 2025, Item 4.B "Business Overview", ReSTART study design

Unpack those two terms, because they carry the weight. Single-arm means every patient gets Alpha DaRT; nobody gets a comparator. There is no group to measure against, so the trial cannot answer "better than what?" — only "what happened to the people we treated". Open label means neither patient nor physician is blinded; everyone knows the experimental therapy is being given, and the person judging whether a tumor shrank knows it too. The gold standard of medicine — the randomized controlled trial, where a coin flip decides who gets the therapy and nobody knows who got it — is the gold standard precisely because it strips out the two things a single-arm open-label study cannot: the natural course of the disease, and hope. In an everyday image: it is a taste test where every taster is told in advance which dish the chef is proud of, and there is no second dish.

To be fair, and this matters: none of this is irregular. Single-arm pivotal trials are common and accepted in device development and in oncology when the population has no curative standard of care — you cannot ethically randomize dying patients to nothing — and the FDA granted the IDE and the Breakthrough Device Designation knowing the design exactly. Alpha Tau is not cutting a corner; it is walking a legitimate path. But the path has a consequence that belongs to you, not to the regulator: a single-arm trial produces a number, not a comparison. If ReSTART reports, say, a 50 percent response rate in the second half of 2026, the honest question — 50 percent versus what those same patients would have done otherwise — will have no answer in the data. The company's own risk factors concede the general point: "The results of preclinical studies and clinical trials of our products conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials." Remember the image: one dish, and every taster was told whose it was.

Uncomfortable truth no. 3: the percentages that carry the story describe three, eight and thirty-two people

Now we go looking for the denominators — and this is where the opening reflex gets its bill. In May 2026 Alpha Tau announced what its own press release called "groundbreaking interim results" from the U.S. REGAIN trial in recurrent glioblastoma, a brain cancer with, as the release rightly says, "virtually no curative options": "100% local disease control, 67% complete response rate". Both numbers are true. Here is the denominator, from the same document: the analysis was run after three patients were treated — one each in December 2025, February and March 2026 — because the FDA had requested an interim safety look before the trial's scope was expanded. Two of those three showed a complete response; the third had stable disease with a 30 percent tumor reduction. Two out of three is 67 percent. It is also two people.

The pattern repeats across the pipeline. In head and neck cancer, combining Alpha DaRT with pembrolizumab, the annual report reports a "37.5% systemic complete response rate and a 75% systemic objective response rate" — as of the January 9, 2025 cutoff, that was eight patients treated, of whom three showed a systemic complete response, three a partial response, and — a detail worth pausing on — two died before being evaluated. The largest published data set is the most sober one: final results from the first-in-human pancreatic cancer study in Montreal, presented at the 2026 ASCO Gastrointestinal Cancers Symposium in January 2026, covering 32 patients with a 22 percent objective response rate and 81 percent disease control (or 23 percent and 87 percent excluding the first two patients, who were deliberately given low doses for feasibility only). Notice the direction: as the denominator grows, the percentage falls. That is not a scandal — it is what regression to the mean looks like, and it is the single most reliable pattern in early clinical data.

And to be scrupulously fair to Alpha Tau: the company does not hide any of this. The patient counts sit in the same paragraphs as the percentages; the three-patient interim analysis is described as exactly that, and its purpose — an FDA-requested safety look — is stated. The filings even concede the general limitation in plain words: earlier results "may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results", and clinical data "are often susceptible to various interpretations and analyses". What the company controls is the press release headline; what you control is whether you read to the denominator. Remember the mechanism: a percentage from three patients is a reason to run the next trial — it is not evidence that the trial will work.

Uncomfortable truth no. 4: nothing is approved in the United States — and the biggest risk is not in the lab

Two facts round out the picture, and they pull in different directions. The first is regulatory. Despite ten years of work, two Breakthrough Device Designations and approvals in Israel and Japan, the U.S. market — the only one that would justify a billion-dollar valuation — remains closed:

"To date, we have not obtained authorization from the FDA to market any product candidate in the United States, and we are currently pursuing PMA approval for our Alpha DaRT technology, which may limit our ability to implement product changes following any potential approval."

— Alpha Tau Medical Ltd., SEC annual report 20-F for 2025, Item 3.D "Risk Factors"

The PMA is the heavyweight route: the filing itself notes it is "much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is submitted". Alpha Tau is filing it modularly — submitting pieces as they are ready, with the non-clinical module already in as of January 2026 — which spreads the work but does not shorten the odds. And note what a Breakthrough Device Designation is and is not: per the FDA's own program description it buys "more interactive and timely communications" and "prioritized review", while expressly "preserving the statutory standards" for approval. It is a faster queue, not a lower bar.

The second fact has nothing to do with medicine. Alpha Tau's people, laboratories and manufacturing sit in Jerusalem, and the annual report says something about that which most investors never read:

"Our commercial insurance does not cover losses resulting from war or terrorist attacks. While the Israeli government has in the past provided compensation for certain damages caused by such events, we cannot assure you that such government compensation programs will continue, or if continued, will be sufficient to compensate us fully for any losses incurred."

— Alpha Tau Medical Ltd., SEC annual report 20-F for 2025, Item 3.D "Risk Factors"

The same section names the mechanism that hits a company like this hardest: prolonged conflicts "have in the past required significant mobilization of military reservists, including personnel employed in the sector in which we operate, which may affect workforce availability". Alpha Tau's own report notes that the majority of its trials and preclinical studies are led internally rather than through external contract research organizations, and that the bulk of R&D spending goes to internal personnel and to manufacturing the Alpha DaRT sources for its own studies. Translated: this company is its people in Jerusalem. To be fair, the report also states that as of its date, regional security conditions had not had a material impact on results — and the risk is one every Israeli issuer carries. But it is an unhedged, uninsurable risk sitting underneath a billion-dollar valuation, and it deserves to be named rather than assumed away.

Valuation: a billion dollars for a probability

In mid-July 2026 Alpha Tau's market value stood at roughly $1.07 billion, across about 90.3 million shares (data as of July 16, 2026). Now try to value it, and watch the standard tools break in your hands. A price-to-sales ratio cannot be computed — the denominator is zero. A price-to-earnings ratio cannot be computed — there have been no earnings, ever, and analysts model a loss of about $0.66 per share for the current year. What remains is the balance sheet, and it gives the plainest reading available: book value per share is about $0.77, which puts the price-to-book ratio around 16. Put concretely: of the roughly $1.07 billion the market assigns this company, about $80 million is money in the bank (March 31, 2026) and essentially all of the rest is the expectation that Alpha DaRT gets approved and sells. That is not a criticism of the price — it is what the price is. Every clinical-stage company is valued this way; the only question is whether the probability being priced matches the evidence on the table.

The professionals' view is unanimous and thin: four analysts cover the stock, and all four are positive — two strong buy, two buy, not a single hold or sell — with an average price target of about $14.20 (data as of July 16, 2026). Treat that consensus for what it is: on a pre-revenue company whose pivotal data has not yet been published, an analyst target is not a measurement but a modeled guess at the same probability you are guessing at, and four voices in unison are less a second opinion than an echo. The nearer-term reality check is on the calendar rather than in the models: the annual report expects ReSTART results in the second half of 2026, and the modular PMA is being assembled around them. That readout is the pivot — it is the first time this technology will be measured against a pre-specified endpoint in a proper pivotal population rather than in a handful of patients. Put differently: the market has already priced the answer to a question the data has not yet been asked.

Opportunities and risks at a glance

What speaks for Alpha Tau:

• A genuinely novel mechanism with a real scientific rationale: Radium-224 seeds whose daughter atoms diffuse a few millimeters through the tumor, harnessing alpha radiation's destructive power while turning its sub-100-micrometer range from a defect into a safety feature (annual report 20-F for 2025, Item 4.B).
• Regulatory progress that is datable, not promissory: marketing approval in Israel (August 2020), two FDA Breakthrough Device Designations (June and October 2021), and Japan's shonin pre-market approval in February 2026 for unresectable locally advanced or recurrent head and neck cancer — the first approval in a major market.
• The pivotal milestone is reached: ReSTART completed enrollment with 88 patients in May 2026, results are expected in the second half of 2026, and the first module of the modular PMA went in in January 2026.
• No going-concern warning anywhere in the filings: $80.2 million of cash, cash equivalents, short-term and restricted deposits (March 31, 2026) against a 2025 operating cash burn of $26.7 million — the company judges its resources adequate for "the foreseeable future".
• Breadth: 11 clinical studies ongoing worldwide as of December 31, 2025, across skin, head and neck, pancreatic and brain tumors, with a safety record the filings describe as favorable — in the pilot U.S. skin study, all ten treated lesions showed a complete response with no product-related serious adverse events.

What speaks against it:

• Not one dollar of revenue since operations began in 2016: a net loss of $42.6 million and an accumulated deficit of $190.1 million (December 31, 2025); the filings expect products to be commercially available only "in many years, if at all".
• The one U.S. pivotal trial is "single-arm, open label" — no control group, no blinding; it will produce a response rate, not a comparison, and the FDA route is a PMA, which the filing itself calls "much more costly and uncertain" than the alternatives and typically takes one to three years or longer.
• The headline percentages rest on tiny denominators: 67 percent complete response = two of three patients (REGAIN, cutoff May 3, 2026); 37.5 percent systemic complete response = three of eight, with two more dead before evaluation (cutoff January 9, 2025); the largest data set, 32 patients, shows a far soberer 22 percent objective response.
• Dilution is structural: the weighted average share count rose 27 percent year over year to 89.7 million (Q1 2026); shares were sold at $2.612 in April 2025 and $6.93 in January 2026; options on 15,985,500 shares plus 597,700 RSUs remain outstanding. R&D spending is rising 53 percent year over year against a fixed cash pile.
• Unhedgeable geography: people, labs and manufacturing sit in Jerusalem, commercial insurance "does not cover losses resulting from war or terrorist attacks", and reservist mobilization can pull staff out of a company whose work is done almost entirely in-house.

A human conclusion

Back to the number we opened with. 67 percent. You now know it means two people out of three, in a safety analysis the FDA asked for before letting the trial grow — and knowing that does not make it worthless. Two complete responses in recurrent glioblastoma, a disease that kills almost everyone it touches and where, as Alpha Tau's own release puts it, there are "virtually no curative options", is a genuinely remarkable thing that happened to two human beings. Hold both thoughts at once, because this is the whole discipline: the finding is real, and it is not yet evidence. Those are not contradictory statements. They are the difference between a reason to keep going and a reason to bet a billion dollars.

What we found in the filings is a company that is more honest than its headlines: the patient counts sit right there next to the percentages, the single-arm design is stated plainly, the war risk is named, and — unlike so many of its peers — there is no going-concern warning to explain away. What we also found is a valuation with nothing underneath it but a probability: no revenue in ten years, roughly $80 million of the $1.07 billion in actual money, and a price-to-book ratio around 16. Between those two findings sits a date: the second half of 2026, when ReSTART finally reports and this technology gets measured against a pre-specified endpoint in 88 patients instead of three. Whether you want to own the bet before that answer arrives — paying today's price for tomorrow's proof — or would rather read the readout first and possibly pay more for certainty, is not a question the filings can settle for you. But at least now, when the next press release leads with a percentage, you will do the thing your brain did not want to do at the top of this page: you will look for the denominator. What you make of it is your decision. And that is exactly as it should be.

Sources

All original documents used in this analysis — to read for yourself:

• Alpha Tau Medical Ltd. — SEC annual report 20-F for 2025 (filed March 9, 2026)
• Alpha Tau Medical Ltd. — SEC interim report 6-K of May 18, 2026, exhibit 99.1: first quarter 2026 financial results and corporate update
• Alpha Tau Medical Ltd. — SEC interim report 6-K of May 11, 2026: interim results of the U.S. REGAIN trial in recurrent glioblastoma
• Alpha Tau Medical Ltd. — SEC annual report 20-F for 2024 (filed March 12, 2025)
• Alpha Tau Medical Ltd.'s complete SEC filing history: EDGAR overview (sec.gov)
• Fundamental data (share count, market value, analyst estimates; data as of July 16, 2026), reconciled with the SEC filings.
• Reddit mentions: ApeWisdom (2 mentions in 24 hours, as of July 16, 2026); our in-house stock scanner carries no company row for DRTS (Israeli issuer outside the Russell 3000 universe).

Transparency & disclaimer: This analysis is a journalistic contextualization of publicly available information and is not investment advice, not a financial analysis in the regulatory sense, and not a solicitation to buy or sell securities. Stock investments carry substantial risks up to total loss. All information without guarantee; the data cut-off is noted in the text in each case. The author holds no position in Alpha Tau Medical stock at the time of publication.